BR112017010298A2 - anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus e usos dos mesmos - Google Patents
anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus e usos dos mesmosInfo
- Publication number
- BR112017010298A2 BR112017010298A2 BR112017010298A BR112017010298A BR112017010298A2 BR 112017010298 A2 BR112017010298 A2 BR 112017010298A2 BR 112017010298 A BR112017010298 A BR 112017010298A BR 112017010298 A BR112017010298 A BR 112017010298A BR 112017010298 A2 BR112017010298 A2 BR 112017010298A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- rabv
- infection
- lysaviruses
- relates
- Prior art date
Links
- 241000711798 Rabies lyssavirus Species 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 210000004180 plasmocyte Anatomy 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
a presente invenção refere-se a anticorpos, e fragmentos de ligação de antígeno dos mesmos, que neutralizam potentemente a infecção de ambos lissavírus rabv e não rabv. a invenção também se refere a sítios antigênicos aos quais os anticorpos e fragmentos de ligação de antígeno se ligam, bem como a ácidos nucleicos que codificam e células b imortalizadas e células plasmáticas cultivadas que produzem tais anticorpos e fragmentos de anticorpos. além disso, a invenção refere-se ao uso dos anticorpos e fragmentos de anticorpos da invenção em métodos de triagem bem como no diagnóstico, na profilaxia e no tratamento da infecção pelo rabv e da infecção com lissavírus não rabv.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122020023406-7A BR122020023406B1 (pt) | 2014-11-18 | 2015-11-18 | Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, moléculas de ácido nucleico, vetor, célula isolada, composição farmacêutica, usos dos mesmos, e kit de partes |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2014/003076 | 2014-11-18 | ||
EP2014003076 | 2014-11-18 | ||
PCT/EP2015/002305 WO2016078761A1 (en) | 2014-11-18 | 2015-11-18 | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112017010298A2 true BR112017010298A2 (pt) | 2017-12-19 |
BR112017010298B1 BR112017010298B1 (pt) | 2023-10-31 |
Family
ID=52339085
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017010298-6A BR112017010298B1 (pt) | 2014-11-18 | 2015-11-18 | Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, usos dos mesmos, molécula de ácido nucleico, vetor, célula isolada, composição farmacêutica, e kit de partes |
BR122020023406-7A BR122020023406B1 (pt) | 2014-11-18 | 2015-11-18 | Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, moléculas de ácido nucleico, vetor, célula isolada, composição farmacêutica, usos dos mesmos, e kit de partes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122020023406-7A BR122020023406B1 (pt) | 2014-11-18 | 2015-11-18 | Anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus, moléculas de ácido nucleico, vetor, célula isolada, composição farmacêutica, usos dos mesmos, e kit de partes |
Country Status (13)
Country | Link |
---|---|
US (4) | US10703801B2 (pt) |
EP (2) | EP3220947B1 (pt) |
CN (2) | CN114805558B (pt) |
BR (2) | BR112017010298B1 (pt) |
DK (1) | DK3220947T3 (pt) |
ES (1) | ES2838679T3 (pt) |
HR (1) | HRP20201811T1 (pt) |
HU (1) | HUE052595T2 (pt) |
LT (1) | LT3220947T (pt) |
PH (2) | PH12017500722A1 (pt) |
PL (1) | PL3220947T3 (pt) |
SI (1) | SI3220947T1 (pt) |
WO (1) | WO2016078761A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019227039A1 (en) * | 2018-05-24 | 2019-11-28 | Lankenau Institute For Medical Research | Compositions comprising antibodies to rabies virus and the uses thereof |
WO2020078568A1 (en) * | 2018-10-19 | 2020-04-23 | Humabs Biomed Sa | Antibodies and methods for treatment of lyssavirus infection |
BR112021008240A2 (pt) * | 2018-11-02 | 2021-10-26 | Cadila Healthcare Limited | Anticorpo monoclonal, coquetel de pelo menos dois anticorpos monoclonais, combinação de um anticorpo monoclonal ou de um coquetel de pelo menos dois anticorpos monoclonais de murino e uma vacina antirrábica, uso de um anticorpo monoclonal ou de um coquetel de pelo menos dois anticorpos monoclonais de murino, composição, conjunto, método, métodos para diagnosticar e detectar raiva e processos para a produção e purificação de um anticorpo |
CN109970852B (zh) * | 2019-04-01 | 2020-10-13 | 浙江大学 | 分泌抗狂犬病毒m蛋白单克隆抗体的杂交瘤细胞株及应用 |
WO2022090484A2 (en) * | 2020-10-29 | 2022-05-05 | The Secretary Of State For Environment, Food And Rural Affairs | Viral vector |
CN114958774B (zh) * | 2022-05-08 | 2023-10-27 | 中国医学科学院医学生物学研究所 | 抗狂犬病病毒单克隆抗体及分泌该抗体的杂交瘤细胞株与应用 |
CN117683123A (zh) * | 2023-09-15 | 2024-03-12 | 东普安凤(北京)生物技术有限公司 | 抗狂犬病毒人源化抗体和抗体组合及其用途 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
CN102936284A (zh) * | 2005-02-02 | 2013-02-20 | 马萨诸塞州大学 | 人抗狂犬病抗体及其用途 |
PL2350128T3 (pl) | 2008-10-22 | 2015-03-31 | Inst Res Biomedicine | Sposoby wytwarzania przeciwciał z komórek plazmatycznych |
CN103596975A (zh) * | 2010-01-04 | 2014-02-19 | 印度免疫有限公司 | 针对狂犬病病毒的重组人二价双链抗体及其用途 |
WO2012054502A1 (en) * | 2010-10-19 | 2012-04-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Identification of antibodies specific for lyssaviruses and methods of their use |
IN2014KN02831A (pt) * | 2012-05-24 | 2015-05-08 | Mountgate Group Ltd |
-
2015
- 2015-11-18 SI SI201531420T patent/SI3220947T1/sl unknown
- 2015-11-18 LT LTEP15798327.1T patent/LT3220947T/lt unknown
- 2015-11-18 BR BR112017010298-6A patent/BR112017010298B1/pt active IP Right Grant
- 2015-11-18 US US15/527,511 patent/US10703801B2/en active Active
- 2015-11-18 ES ES15798327T patent/ES2838679T3/es active Active
- 2015-11-18 HU HUE15798327A patent/HUE052595T2/hu unknown
- 2015-11-18 PL PL15798327T patent/PL3220947T3/pl unknown
- 2015-11-18 EP EP15798327.1A patent/EP3220947B1/en active Active
- 2015-11-18 CN CN202210166356.7A patent/CN114805558B/zh active Active
- 2015-11-18 WO PCT/EP2015/002305 patent/WO2016078761A1/en active Application Filing
- 2015-11-18 EP EP20200023.8A patent/EP3831404A1/en active Pending
- 2015-11-18 DK DK15798327.1T patent/DK3220947T3/da active
- 2015-11-18 BR BR122020023406-7A patent/BR122020023406B1/pt active IP Right Grant
- 2015-11-18 CN CN201580073641.2A patent/CN107428819B/zh active Active
-
2017
- 2017-04-19 PH PH12017500722A patent/PH12017500722A1/en unknown
-
2020
- 2020-05-22 US US16/882,359 patent/US11723977B2/en active Active
- 2020-05-22 US US16/882,354 patent/US11730813B2/en active Active
- 2020-11-13 HR HRP20201811TT patent/HRP20201811T1/hr unknown
-
2021
- 2021-03-10 PH PH12021550521A patent/PH12021550521A1/en unknown
-
2023
- 2023-08-22 US US18/454,011 patent/US20240050565A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DK3220947T3 (da) | 2020-11-30 |
BR112017010298B1 (pt) | 2023-10-31 |
EP3831404A1 (en) | 2021-06-09 |
EP3220947A1 (en) | 2017-09-27 |
CN114805558A (zh) | 2022-07-29 |
HUE052595T2 (hu) | 2021-05-28 |
PH12017500722A1 (en) | 2017-10-09 |
CN114805558B (zh) | 2023-12-29 |
PL3220947T3 (pl) | 2021-05-31 |
US11730813B2 (en) | 2023-08-22 |
US20180105579A1 (en) | 2018-04-19 |
SI3220947T1 (sl) | 2021-02-26 |
US20240050565A1 (en) | 2024-02-15 |
BR122020023406B1 (pt) | 2023-10-31 |
LT3220947T (lt) | 2020-12-28 |
US10703801B2 (en) | 2020-07-07 |
PH12021550521A1 (en) | 2022-02-14 |
CN107428819A (zh) | 2017-12-01 |
US11723977B2 (en) | 2023-08-15 |
ES2838679T3 (es) | 2021-07-02 |
US20200354435A1 (en) | 2020-11-12 |
US20200354436A1 (en) | 2020-11-12 |
HRP20201811T1 (hr) | 2021-01-08 |
WO2016078761A1 (en) | 2016-05-26 |
CN107428819B (zh) | 2022-03-15 |
EP3220947B1 (en) | 2020-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018074456A2 (pt) | anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos | |
BR112017010298A2 (pt) | anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus e usos dos mesmos | |
BR112018071276A2 (pt) | anticorpos anti-il-33, composições, métodos e usos dos mesmos | |
CO2018012415A2 (es) | Proteínas de unión específica y usos de las mismas | |
BR112018002406A2 (pt) | anticorpos que neutralizam potentemente o vírus da hepatite b e usos dos mesmos | |
BR112018012352A2 (pt) | anticorpos anti-lag3 e fragmentos de ligação ao antígeno | |
EA201791961A1 (ru) | Антитела, специфичные к cd47 и pd-l1 | |
BR112019004998A2 (pt) | anticorpos anti-pd-1(cd279) | |
CU20180024A7 (es) | Moléculas de unión a linfopoyetina estromal tímica (tslp), composiciones farmacéuticas que las contienen y método de producción de las mismas | |
BR112017001579A2 (pt) | anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos | |
BR112018000769A2 (pt) | anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos | |
PH12016500823A1 (en) | Production of t cell retargeting hetero-dimeric immunoglobulins | |
BR112017009813A2 (pt) | conjugados de anticorpo fármaco | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
BR112017003108A2 (pt) | anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno | |
UY36889A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
BR112019005726A8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno | |
MX2014000749A (es) | Anticuerpos neutralizantes del virus de la influenza a y usos de estos. | |
BR112015023262B8 (pt) | Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
CY1122214T1 (el) | Αντισωματα ειδικα για ton fcrn | |
CL2020000467A1 (es) | Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. | |
BR112018076089A2 (pt) | processo de preparação de anticorpos anti-amh e usos dos mesmos | |
BR112014023063A2 (pt) | anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos | |
WO2016075546A3 (en) | Antibodies that neutralize ebola virus and uses thereof | |
MA40526A (fr) | Protéines de fixation antigénique fixant le cxcr3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: INSTITUT PASTEUR (FR) ; HUMABS BIOMED SA (CH) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/11/2015, OBSERVADAS AS CONDICOES LEGAIS |